Released by the U.S. Department of Health and Human Services (HHS), this report provides the recommended framework for the screening of orders to ensure manufacture compliance with current regulations and reduce the risk of supplying products to individuals that may exploit this dual-use technology for malicious intent. The primary goal of the Screening Framework Guidance for Providers of Synthetic Double-Stranded DNA is to minimize the risk that unauthorized individuals or individuals with malicious intent will obtain “toxins and agents of concern” through the use of nucleic acid synthesis technologies, and to simultaneously minimize any negative impacts on the conduct of research and business operations. The Guidance was developed, in light of providers’ existing protocols, to be implemented without unnecessary cost and to be globally extensible, both for U.S.-based providers operating abroad and for international providers.
Screening Framework Guidance for Providers of Synthetic Double-Stranded DNA
- October 13, 2010
- | Filed under North America, Featured, Report, and 2001-2025
